Resistant Gram-negative infections in the outpatient setting in Latin America

被引:40
|
作者
Salles, M. J. C. [1 ]
Zurita, J. [2 ]
Mejia, C. [3 ]
Villegas, M. V. [4 ]
机构
[1] Santa Casa Sao Paulo Sch Med, Dept Internal Med, Sao Paulo, Brazil
[2] Pontificia Univ Catolica Ecuador, Hosp Vozandes, Fac Med, Quito, Ecuador
[3] Hosp Roosevelt, Infect Dis Unit, Guatemala City, Guatemala
[4] Int Ctr Med Res & Training CIDEIM, Bacterial Resistance Grp, Cali, Colombia
来源
EPIDEMIOLOGY AND INFECTION | 2013年 / 141卷 / 12期
关键词
Drug resistance; Gram-negative; intra-abdominal infection; Latin America; outpatient; urinary tract infection; SPECTRUM-BETA-LACTAMASE; URINARY-TRACT-INFECTIONS; RIO-DE-JANEIRO; EXTENDED-SPECTRUM; ESCHERICHIA-COLI; ANTIMICROBIAL RESISTANCE; RISK-FACTORS; MOLECULAR CHARACTERISTICS; TRIMETHOPRIM-RESISTANT; COMPANION ANIMALS;
D O I
10.1017/S095026881300191X
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Latin America has a high rate of community-associated infections caused by multidrug-resistant Enterobacteriaceae relative to other world regions. A review of the literature over the last 10 years indicates that urinary tract infections (UTIs) by Escherichia coli, and intra-abdominal infections (IAIs) by E. coli and Klebsiella pneumoniae, were characterized by high rates of resistance to trimethoprim/sulfamethoxazole, quinolones, and second-generation cephalosporins, and by low levels of resistance to aminoglycosides, nitrofurantoin, and fosfomycin. In addition, preliminary data indicate an increase in IAIs by Enterobacteriaceae producing extended-spectrum beta-lactamases, with reduced susceptibilities to third-and fourth-generation cephalosporins. Primary-care physicians in Latin America should recognize the public health threat associated with UTIs and IAIs by resistant Gram-negative bacteria. As the number of therapeutic options become limited, we recommend that antimicrobial prescribing be guided by infection severity, established patient risk factors for multidrug-resistant infections, acquaintance with local antimicrobial susceptibility data, and culture collection.
引用
收藏
页码:2459 / 2472
页数:14
相关论文
共 50 条
  • [31] INFECTIONS WITH GRAM-NEGATIVE BACILLI
    HUNTER, WF
    ATKINSON, HM
    PATHOLOGY, 1969, 1 (02) : 155 - &
  • [32] INFECTIONS WITH GRAM-NEGATIVE RODS
    DAVIES, PA
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1979, 5 : 13 - 20
  • [33] GRAM-NEGATIVE BACILLARY INFECTIONS
    DUMA, RJ
    AMERICAN JOURNAL OF MEDICINE, 1985, 78 (6A): : 154 - 164
  • [34] GRAM-NEGATIVE ROD INFECTIONS
    不详
    DISEASES OF THE CHEST, 1962, 42 (03): : 344 - 344
  • [35] Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections
    Tamma, Pranita D.
    Heil, Emily L.
    Justo, Julie Ann
    Mathers, Amy J.
    Satlin, Michael J.
    Bonomo, Robert A.
    CLINICAL INFECTIOUS DISEASES, 2024,
  • [36] ANTIBIOTIC-RESISTANT GRAM-NEGATIVE BACTERIA IN THE CRITICAL CARE SETTING
    TOLTZIS, P
    BLUMER, JL
    PEDIATRIC CLINICS OF NORTH AMERICA, 1995, 42 (03) : 687 - 702
  • [37] Infections caused by resistant Gram-negative bacilli: New molecules and combinations
    Cattoir, V.
    JOURNAL DES ANTI-INFECTIEUX, 2013, 15 (04) : 159 - 165
  • [38] CEFAMANDOLE THERAPY OF CEPHALOTHIN-RESISTANT GRAM-NEGATIVE BACILLARY INFECTIONS
    KOPP, PE
    SIEBERT, WT
    WILLIAMS, TW
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1984, 35 (04): : 627 - 632
  • [39] Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections
    Drwiega, Emily N.
    Griffith, Nicole C.
    Danziger, Larry H.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2022, 18 (04) : 245 - 259
  • [40] Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections
    Khalid Eljaaly
    Aisha Alharbi
    Samah Alshehri
    Jessica K. Ortwine
    Jason M. Pogue
    Drugs, 2019, 79 : 243 - 269